ArticleThe journal of allergy and clinical immunology. Global2026
Real-life safety of peanut oral immunotherapy: Results from a French multicenter observational study.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taste aversion and adverse events contribute equally to OIT discontinuation in children: A real-world multi-allergen analysis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peanut oral immunotherapy (POIT) has been widely used in France for more than 10 years. However, the overall "real-life" safety of POIT has not been evaluated to date. Objective: We sought to describe the number, severity, and circumstances of allergic reactions (ARs) in patients undergoing POIT. Methods: We performed a retrospective multicenter study from November 2019 to July 2021 in 12 French centers, including patients with peanut allergy who were older than 3 years and treated by POIT for 6 months or more. Data collected from the patients' charts about ARs occurring during the previous year included the number, severity (using the Astier score grades 1-5), and circumstances of all immediate allergic reactions (IARs) and non-IARs. Results: Among the 295 patients included, 46 (15.6%) experienced an IAR, accounting for a total of 75 IARs. The IARs were mainly grade 1; however, 22 (29.3%) were defined as a serious systemic reaction (ie, Astier score grade ≥ 3) and 8 (10.6%) were managed by epinephrine injection at home. Proven cofactors were involved in 38 of 73 IARs (52.1%): exercise in 65.8%, fatigue in 18.4%, stress in 13.2%, irregular peanut intake in 5.3%, and pollen exposure in 5.3%. The use of epinephrine was more frequent when a cofactor was involved (0% vs 18.4%; Conclusions: Although POIT is safe for most patients, some severe IARs influenced by cofactors may occur several months after the beginning of the process. These results highlight the overriding importance of maintaining therapeutic education, especially about risk cofactors, throughout oral immunotherapy programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.